Advertisement

CHMP issues positive opinion for avelumab for metastatic Merkel cell carcinoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Merck KGaA, which operates its biopharmaceutical business as EMD Serono in the U.S. and Canada, and Pfizer Inc. said the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of avelumab (Bavencio) as a monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Advertisement
Advertisement
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

In an effort to target the right patients, genetic screening is becoming more common in clinical trials. But incorporating it can be complex and add a significant burden for both patients and clinical trial sites. Genetic counseling can streamline that process and help drug and gene therapy developers expedite the recruitment of genetically-eligible participants for their trials and use genetic testing results to accelerate the speed and success of clinical trials.
Advertisement
Advertisement